MU Research Reactor announces commercial shipments of breakthrough radioisotope for cancer treatment
MU Research Reactor announces commercial shipments of breakthrough radioisotope for cancer treatmentCOLUMBIA, Mo. — The University of Missouri Research Reactor (MURR) recently completed its first commercial shipment of no-carrier-added lutetium-177 (NCA Lu-177) for human use and is providing weekly deliveries to Novartis for use in cancer treatments. These shipments are a significant milestone in a […]